completed · Health
Production of Thermo-stable Newcastle disease vaccine Nepal
Poultry consumption is on the rise in Nepal, although still low compared to neighbouring countries. An estimated 230 million chickens are raised in backyards every year. Seventy percent of the total stock dies in the rainy season due to avian flu (AF) and Newcastle disease (ND). The major poultry farms (producing another 70 million chickens) are able to vaccinate their stock. Because Newcastle vaccines are thermos-unstable, they cannot be used in remote areas where the majority of Nepal's rural population lives. Paid for by the Australian Government, a thermo stable ND vaccine was developed in Australia. This vaccine survives thirty days of tropical temperatures and is affordable for smallholders.The local partner, Intrepid Nepal Pvt. Ltd is a company of thirty highly qualified employees that focuses on Molecular Diagnostics Platforms. Their area of work is detection of pathogens, human and animal. One of their activities is epidemical research. In this way, they got a clear picture of the ND problem and decided to produce this thermos-stable vaccine using the Australian seeds, that are non-commercially available. In the poultry production chain, such a vaccine is the missing link. As this is to be the first commercial production of a vaccine from this seed, the Australian government is eager to facilitate this by providing expertise and seeds free of costs. USAID and an NGO have already pledged to buy thermos-stable vaccine for seven million chickens and resell them to smallholders. The business includes diagnosing whether it makes sense to vaccinate in a certain area, determining the ND strain rampant and the production of the vaccine itself. In order to get sufficient starting capital, they were introduced to the applicant by Dutch businessmen active in Nepal.The applicant, Aleven B.V., is an asset manager that invests on behalf of his Dutch clients in food and health related companies in Nepal, Georgia and the Philippines. The other project partner, One to Watch B.V., is a developer of Nepali companies active in food and health. The three partners will start a joint venture that enables Intrepid to start the production of vaccine on their premises.
Overview
About this project
Poultry consumption is on the rise in Nepal, although still low compared to neighbouring countries. An estimated 230 million chickens are raised in backyards every year. Seventy percent of the total stock dies in the rainy season due to avian flu (AF) and Newcastle disease (ND). The major poultry farms (producing another 70 million chickens) are able to vaccinate their stock. Because Newcastle vaccines are thermos-unstable, they cannot be used in remote areas where the majority of Nepal's rural population lives. Paid for by the Australian Government, a thermo stable ND vaccine was developed in Australia. This vaccine survives thirty days of tropical temperatures and is affordable for smallholders.The local partner, Intrepid Nepal Pvt. Ltd is a company of thirty highly qualified employees that focuses on Molecular Diagnostics Platforms. Their area of work is detection of pathogens, human and animal. One of their activities is epidemical research. In this way, they got a clear picture of the ND problem and decided to produce this thermos-stable vaccine using the Australian seeds, that are non-commercially available. In the poultry production chain, such a vaccine is the missing link. As this is to be the first commercial production of a vaccine from this seed, the Australian government is eager to facilitate this by providing expertise and seeds free of costs. USAID and an NGO have already pledged to buy thermos-stable vaccine for seven million chickens and resell them to smallholders. The business includes diagnosing whether it makes sense to vaccinate in a certain area, determining the ND strain rampant and the production of the vaccine itself. In order to get sufficient starting capital, they were introduced to the applicant by Dutch businessmen active in Nepal.The applicant, Aleven B.V., is an asset manager that invests on behalf of his Dutch clients in food and health related companies in Nepal, Georgia and the Philippines. The other project partner, One to Watch B.V., is a developer of Nepali companies active in food and health. The three partners will start a joint venture that enables Intrepid to start the production of vaccine on their premises.
Progress
86%- Plan
- Implementation
- Outcomes
Alignment